As the November 3 midterm elections approach, President Donald Trump has been vocal about his administration’s drug pricing initiatives, asserting that the U.S. now enjoys the lowest prescription drug prices globally. “This one thing alone should win us the midterms,” he stated during a recent press briefing at the White House.
Since its launch in February, TrumpRx.gov has expanded significantly. Originally featuring a limited selection of brand-name drugs, the site now boasts over 800 listings, offering discounts on various medications ranging from popular weight loss treatments to essential cancer and rheumatoid arthritis therapies.
Despite these claims, it remains uncertain whether Americans are truly reaping the financial benefits promised by Trump. A recent analysis indicates that, while prescription drug prices dropped by 3.1% over the year ending in July, attributing this decrease directly to Trump’s drug pricing strategies is complex. The site relies heavily on data and technology from GoodRx, merging existing discounts with newly negotiated prices.
At a recent Republican midterm convention, Trump proclaimed, “We went from the highest prescription drug prices, by far, anywhere in the world, to the lowest prescription drug prices anywhere in the world.” Yet, a study by KFF revealed that while TrumpRx prices can be lower for a handful of cancer and cholesterol medications, many American consumers still face higher prices compared to international standards.
The KFF report found that for 32 brand-name drugs examined, TrumpRx prices were lower for 17 but higher for 15, contradicting Trump’s assertions of universal low pricing. In fact, only five of the drugs were found to be the cheapest available globally, while 13 were pricier than counterparts in other wealthy nations.
One striking example is Ozempic, a leading diabetes medication, which costs $349 through TrumpRx, significantly higher than the average price in several other affluent countries. Another medication, Enbrel, is priced at $3,354 through TrumpRx—over five times the average price elsewhere. Conversely, some drugs, like Rydapt, show competitive pricing, costing $2,909 in the U.S. compared to $5,901 in France.
This mixed landscape highlights the challenges and variabilities within Trump’s pricing approach, underscoring that while some lower prices exist, they are not consistent across all medications. Experts point out that the TrumpRx site primarily features selected products from manufacturers willing to offer discounts, which may not reflect the broader market dynamics impacting the most commonly prescribed drugs.
In summary, while the intent behind TrumpRx is to offer significant savings, the reality is a complex interplay of pricing that varies widely and does not always deliver the lowest prices as claimed. As the midterms draw closer, the efficacy and impact of these drug pricing initiatives will likely remain a pivotal topic in the political discourse.
Photo credit: Kent Nishimura
